The noted P/E ratio is inflated by the leveraged structure rather than fundamental earnings performance, making traditional P/E interpretation limited. Underlying index constituents trade at a reasonable forward P/E discount which supports the sector exposure value.

Price-to-sales metrics are unavailable due to the ETF structure; however, the underlying sector benefits from solid growth prospects driving revenue appreciation in healthcare services and biotech, indirectly supporting price multiples.

Enterprise value to EBITDA ratios are not meaningfully calculated for the ETF itself but tend to be moderate within the healthcare sector, underlining an attractive cash flow and earnings profile in underlying holdings which backs the leveraged product's potential returns.

The healthcare sector combines defensive elements with growth drivers like aging populations and innovation, making it resilient in turbulent markets and attractive for leveraged exposure. Regulatory risks and sector-specific volatility persist but are partly offset by secular growth trends in biotech and services.

The projected healthcare sector growth and momentum justify a premium valuation for leveraged exposure, as reflected in analyst targets implying strong upside potential despite elevated operating costs of the ETF itself.

Historically, CURE has demonstrated significant short-term growth aligned with leveraged daily performance but experiences decay and volatility risk over longer periods due to compounding effects. Current valuations and technical signals are consistent with prior phases of tactical opportunity rather than long-term holding.

Key risks include amplified volatility due to 3X leverage, path-dependent decay from daily rebalancing, relatively high expense ratios eroding returns, regulatory changes impacting healthcare sectors, and market rotations that can sharply impair leveraged ETF performance. These risks mandate active management and short-term positioning strategies.